热门资讯> 正文
Olema在乳腺癌候选人Palazestrant的数据中下降了30%
2025-10-20 21:16
- Olema Pharmaceuticals (NASDAQ:OLMA) plunged 30% in pre-market trading Monday after announcing new data from a phase 1b/2 trial of palazestrant in breast cancer.
- The candidate is under investigation in combination with Novartis' (NVS) Kisqali (ribociclib) for HR+/HER- advanced or metastatic breast cancer.
- Patients received either 90 mg or 120 mg of palazestrant plus 600 mg Kisqali daily.
- Results showed that with a median follow-up of 10.8 months, those in the 90 mg group did not reach progression-free survival. Those in the 120 mg cohort, with a median follow-up of over 19 months, median PFS was 15.5 months.
- Olema said that palazestrant was well tolerated with most treatment-emergent adverse events being grade 1 or 2.
More on Olema Pharmaceuticals
- Biggest stock movers Monday: PLUG, RANI, and more
- Goldman's 48 potential M&A candidates
- Seeking Alpha’s Quant Rating on Olema Pharmaceuticals
- Historical earnings data for Olema Pharmaceuticals
- Financial information for Olema Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
